CN106668518A - 回族中药六味血癌康颗粒及其制备方法 - Google Patents
回族中药六味血癌康颗粒及其制备方法 Download PDFInfo
- Publication number
- CN106668518A CN106668518A CN201510749261.8A CN201510749261A CN106668518A CN 106668518 A CN106668518 A CN 106668518A CN 201510749261 A CN201510749261 A CN 201510749261A CN 106668518 A CN106668518 A CN 106668518A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- ingredient particles
- hui nationality
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 47
- 208000032839 leukemia Diseases 0.000 title claims abstract description 26
- 239000002245 particle Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000004615 ingredient Substances 0.000 title abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000605 extraction Methods 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 3
- 239000000284 extract Substances 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- -1 pressure filtration Substances 0.000 claims description 9
- 238000011085 pressure filtration Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 7
- 239000010231 banlangen Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 235000020985 whole grains Nutrition 0.000 claims description 6
- 241000219784 Sophora Species 0.000 claims description 5
- 241000411851 herbal medicine Species 0.000 claims description 5
- 235000013599 spices Nutrition 0.000 claims description 5
- 240000004274 Sarcandra glabra Species 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 241000031023 Amana edulis Species 0.000 claims description 3
- 229920001617 Vinyon Polymers 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000428 dust Substances 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 229910001220 stainless steel Inorganic materials 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 32
- 201000011510 cancer Diseases 0.000 abstract description 24
- 201000010099 disease Diseases 0.000 abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 16
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 3
- 206010009944 Colon cancer Diseases 0.000 abstract description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 2
- 230000006866 deterioration Effects 0.000 abstract description 2
- 238000005469 granulation Methods 0.000 abstract description 2
- 230000003179 granulation Effects 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 241001250596 Pleione Species 0.000 abstract 1
- 241000736026 Sarcandra Species 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 206010017758 gastric cancer Diseases 0.000 abstract 1
- 201000011549 stomach cancer Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 241000227653 Lycopersicon Species 0.000 description 5
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 2
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 2
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 2
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 241001050782 Patrinia heterophylla Species 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002895 emetic Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940097275 indigo Drugs 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- CRDNMYFJWFXOCH-UHFFFAOYSA-N indirubin Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 201000002266 mite infestation Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229930015582 oxymatrine Natural products 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BUOLSBLQAQNNJC-ROVCOPEHSA-N (4ar,5s,6r,6ar,6as,6br,8ar,10s,12ar,14bs)-5,6,10-trihydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)[C@@H](O)[C@@H](O)[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C BUOLSBLQAQNNJC-ROVCOPEHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 240000001606 Adenanthera pavonina Species 0.000 description 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 1
- 241000220433 Albizia Species 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 206010002515 Animal bite Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- YKOPWPOFWMYZJZ-FMMUPTMQSA-N Echinocystic acid Natural products C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)C[C@H](O)[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C YKOPWPOFWMYZJZ-FMMUPTMQSA-N 0.000 description 1
- YKOPWPOFWMYZJZ-UHFFFAOYSA-N Echinocystsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C YKOPWPOFWMYZJZ-UHFFFAOYSA-N 0.000 description 1
- BUOLSBLQAQNNJC-UHFFFAOYSA-N Entagenic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)C(O)C(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C BUOLSBLQAQNNJC-UHFFFAOYSA-N 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 101000633503 Homo sapiens Nuclear receptor subfamily 2 group E member 1 Proteins 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- YAPAFDNQABLIIN-UHFFFAOYSA-N N1,N10-Dicoumaroylspermidine Natural products CC(C)=CCC1=C(O)C(CC=C(C)C)=CC(C=CC(=O)C=2C(=C(CC=C(C)C)C(O)=CC=2)O)=C1 YAPAFDNQABLIIN-UHFFFAOYSA-N 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 102100029534 Nuclear receptor subfamily 2 group E member 1 Human genes 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241000606264 Patrinia Species 0.000 description 1
- 235000019109 Patrinia villosa Nutrition 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- YAPAFDNQABLIIN-XNTDXEJSSA-N Sophoradin Chemical compound CC(C)=CCC1=C(O)C(CC=C(C)C)=CC(\C=C\C(=O)C=2C(=C(CC=C(C)C)C(O)=CC=2)O)=C1 YAPAFDNQABLIIN-XNTDXEJSSA-N 0.000 description 1
- RFAOSYMVZBUVLO-UHFFFAOYSA-N Sophoradin Natural products COC(=O)CCC1(C)C(CCC2(C)C1CCC3C(CCC23C)C(C)(O)CCC=C(C)C)C(=C)C RFAOSYMVZBUVLO-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- VGSYCWGXBYZLLE-QEEQPWONSA-N Trifolirhizin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2[C@H](C3=CC=4OCOC=4C=C3O2)CO2)C2=C1 VGSYCWGXBYZLLE-QEEQPWONSA-N 0.000 description 1
- FCRUGSNPZLERNO-UHFFFAOYSA-N Trifolirhizin Natural products OCC1OC(Oc2ccc3C4Oc5c6OCOc6ccc5C4COc3c2)C(O)C(O)C1O FCRUGSNPZLERNO-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000792902 Valerianaceae Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- XDLDASNSMGOEMX-UHFFFAOYSA-N benzene benzene Chemical compound C1=CC=CC=C1.C1=CC=CC=C1 XDLDASNSMGOEMX-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000002122 leukaemogenic effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- VGSYCWGXBYZLLE-UHFFFAOYSA-N maackiain 3-O-beta-D-galactopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2C(C3=CC=4OCOC=4C=C3O2)CO2)C2=C1 VGSYCWGXBYZLLE-UHFFFAOYSA-N 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 229930014456 matrine Natural products 0.000 description 1
- MCHWKJRTMPIHRA-UHFFFAOYSA-N n-(pyrrolidin-2-ylmethyl)aniline Chemical compound C1CCNC1CNC1=CC=CC=C1 MCHWKJRTMPIHRA-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000001702 nutmeg Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229940097411 palm acid Drugs 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 201000008006 pharynx cancer Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 201000011598 pylorus cancer Diseases 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010043688 thyroid adenoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明详述了回族中药六味血癌康颗粒的配方及其制备方法,该药是一种治疗白血病的绿色高科技中草药,它是以肿节风、山豆根、山慈菇、板蓝根等中草药按一定比例混合加水煎熬、提取、浓缩、造粒而成的中药颗粒,主治白血病,兼治咽喉癌、胃癌、大肠癌等消化系统癌症,本发明的特点是药味少,剂量适中,所选之药都是被现代医学药理实验证明是能够治疗癌症的,它以很低的花费,从根本上改善身体机能,防治病情恶化,恢复身体健康。
Description
技术领域
本发明涉及的回族中药六味血癌康颗粒是一种预防和治疗白血病的绿色高科技中草药。本发明还涉及该药的制备方法,属于中医药类。
背景技术
据《2014年中国肿瘤登记年报》数据显示,按照中国人平均74岁的寿命计算,中国人一生患恶性肿瘤的几率是22%,平均每分钟有6人被诊断为恶性肿瘤,肿瘤在中国已经成为一种常见疾病。目前中国的癌症患者约为800多万人,且每年以100多万人的速度在增加(也有资料显示每年以312万人的速度在增加)。而全世界呢?
据统计,在我国近800万的癌症患者中,白血病的发病率和发病人数虽然还不是前10位,每年发病率约占人口的5/10万,大约8-9万人,但是死亡率却和排在前十位的肺癌、肝癌、乳腺癌等癌病一样的高,这导致了很多患者失去了对生活的信心。白血病由于恶性细胞克隆无节制地不断增殖,大量增殖细胞在空间上挤占了骨髓腔,结果引起骨髓衰竭和全身组织器官受浸害,由于白血病细胞能产生一些体液抑制因子,如酸性同种铁蛋白(isoferritin)等抑制正常造血细胞的增殖,由此便产生了临床一系列的症状和体征。且最要命的是尽管有些人家庭经济并不拮据,但是由于全国所有的肿瘤医院都长年长年的人满为患,因而能抢到一个治疗的床位,能享受到一些名家医院的正规治疗——包括过度治疗——的白血病患者还是相当少的,再加上白血病的治疗比较困难,许多还需要造血干细胞移植、脐血干细胞移植、基因治疗等,如此就更使许多许多尚有生存余地的白血病患者加速走向了死亡的道路。
白血病的发病原因大致有三,一是化学因素,这个原因可能不常见,因为前提必须是患者长期接触某些化学品,如苯,苯的致白血病作用比较肯定。苯致急性白血病以急性粒细胞白血病和红白血病为主。二是遗传因素,这个发病因素至今还未证明,临床上之所以这么认为的原因,是白血病患者中有白血病家族史者占百分八,是比较常见的原因所以不能忽略。三是病毒,如果患者在前期就患有其它疾病的话,如某些肿瘤,这时候就有可能发生白血病了,因为大多数脊椎动物同源的基因都是源瘤基因,所以这也是引起白血病的病因之一。尽管白血病的发病原因在临床上还有很多争议,但是上述的三种是比较常见的。
目前治疗白血病的最好方法是到正规的大医院进行正规的化疗,ALL的治愈率可以达到80%以上,ANLL的治愈率也可达到50%。那些化疗不能治愈的慢性髓细胞白血病病人,还可以通过造血干细胞移植治疗,也有50%-60%的治愈可能。但是各种治疗技术又都有其自身优势和不足,比如造血干细胞移植技术,能使过去无法治愈的高危或复发难治性白血病患者获得治愈机会,但又有价格昂贵、引起排斥反应等不足;而化疗呢,化疗不但副作用大,患者痛苦难以忍受,而且需要数年的时间,成功率也不是100%……
白血病是一种全身性的恶性肿瘤。中医学并无白血病的病名,但就其临床表现多属“血证”、“血虚”、“虚劳”、“恶核”等范畴。白血病是目前较难治愈的疾病,但难治并不代表没法可治,除上述西医治疗方法外,中医也有很多有效的治疗方法。已有的临床证明中药对本病疗效缓和稳定,可减少化疗的毒副作用,不产生耐药,白血病的各期均可应用。中医以整体观念根据患者的全身特点辨证论治,可以适用于各型各期癌症。中医药治疗癌症的优势在于有利于稳定病情,毒副作用轻微、症状改善较明显,使病情发展减慢、肿瘤缩小或带瘤较长期生存,患者易于接受和费用比较低廉。目前西医也认为中医药可以作为癌症的辅助治疗,有助于减少放、化疗的毒性,改善癌症相关症状,提高生存质量,延长生存期。但存在的问题是中医的药方统一性较差,治疗主要凭的是经验。从已有的治癌验方、偏方看,所选中草药药材中总是有一些——多数是超过半数以上的——药物都是没有被现代医学药理实验证明是有治癌功能和作用的“辨证施治”的“配伍”药,本发明人认为挺不合适;而偏方呢,偏方治病靠的是试验,往往耽搁治病的时间。
发明内容
本发明的目的,就是针对中国癌症患者就诊难以及中医病方统一性差、可重复性差、高级别的循证医学理论和证据相对缺乏,因而治癌主要是凭经验等不足之情况,提出一种新的配药方法以及制备方法,提供一种从预防开始,降低白血病的发病率,从癌变开始减缓其进展速度诱导诱导其凋亡或分化恢复为正常细胞的绿色高科技中草药,以很低的花费,从根本上改善身体机能,从而恢复健康。它的最大优势在于能最大限度地诱导癌细胞自我凋亡与分化,促使其逐步恢复正常状态。在具体的配方中,还配合辨证施治,根据白血病的成因系“血证”、“血虚”、“虚劳”、“恶核”等特点,根据患者的具体情况,分别采用不同的配方,运用扶正祛邪清补兼施之法,或补气养阴、健脾和肝,或益肾填精、健脾补肾,或清热解毒、活血化瘀,或健脾和胃、大补气血……做到清不伤正,补不留邪,清中有补,标本兼顾,相辅相成,给造血系统创造一个良好的内部环境,以加快造血功能的恢复,以纠正正气内虚、邪凝毒聚和脏腑阴阳失调功能降低失去平衡致免疫功能低下之不足,调整并提高机体的免疫功能,以达到清补兼施整体抑病的目的,从而提高白血病治疗的整体疗效和远期疗效,为白血病患者提供一种已经被现代医学药理实验证明是有治癌功能和作用的绿色高科技中草药配方以及配制方法,以很低或是较低的花费,从根本上改善身体机能,控制病情的恶化并使病情逐渐好转,最终恢复身体健康。由此也给患者一个根据个人病情、经济状况、个人意愿来综合考虑选择不同治疗方法或几种方法合用特别是中西医相结合综合治疗应用的余地,以期获得最佳疗效,轻松提高生存率——特别是5年以上生存率。
本发明所提出的技术方案是:
一、所述的预防和治疗白血病的回族中药六味血癌康颗粒及其制备方法,是由下列六味原料的重量配比制成的:
肿节风30g、 山豆根30g、山慈菇5g、庆巴消夏1g、
板蓝根15g、 墓回头10g
此方为一日一剂煎服的基本方。在实际应用时,还可根据患者的体质及病症情况,增加1-3味中医“天人合一、辩证论治”理论的“辨证配伍”药。
考虑到用该基本方煎服汤药量大、味道欠佳,患者很难饮用,故必须应用特殊工艺进行制备。
二、将上述各原料制成本发明所述的中药颗粒的制备方法为:
A、 提取物的制备
(1)、提取
a、第一次提取:将上述中草药的重量除庆巴消夏、墓回头以外,全部放大10倍,清水清洗后,置于BT-2 不锈钢提取釜中,加7-9 倍自来水后,加热至100℃恒温提取1小时左右,分离提取液,加压过滤,滤液备用。
b、第二次提取:往提取釜内加入5-7倍量的自来水,加热至100℃恒温提取半小时左右,分离提取液,加压过滤,滤液备用。
c、第三次提取:往提取釜内加入3-5倍量的自来水,加热至100℃恒温提取20分钟左右,分离提取液,加压过滤,滤液备用。
(2)、浓缩
将三次的提取液合并,置于B-500 型三效真空高能蒸发浓缩器内,减压( 负200mmHg),加热至80℃,浓缩至相对密度1.10 ~ 1.20,备用。
(3)、制粉
将庆巴消夏1g、墓回头10g各放大10倍,一同粉碎为末,过100目筛,备用。
(4)、配料
在30 万级洁净车间内,将上述药粉与前述浓缩物以及适量蜂蜜水一起置混合机中充分混合,搅拌均匀。
(5)烘干、粉碎
将混合均匀的药料置于烘箱中60-70℃烘烤4-5小时,然后粉碎,过100 目筛。
(6)造粒
将混合均匀的药料置入造粒机中造粒。
(7)整粒
将制好的颗粒进行整粒,过35目筛。
(8)干燥
将整好的颗粒置入热循环干燥箱内,80℃下通风干燥至水分<8%。
B、包装
先将制好的颗粒装入聚乙烯塑料小袋中,每袋7g,再将装好的小袋装盒、装箱、灭菌(采用60Co辐照,辐照剂量为8kGy)。
、入库
将辐照过的成品按先进先出的原则进行入库。
本发明常规服用方法:上述颗粒每日三次,每次1袋(7g),空腹服用( 服后半小时不可大量喝水,以免冲淡药液)。服药期间勿食用辛辣等对胃肠道刺激性较大的食物。
此药若以煎西红柿汤做药引子服用,效果更佳。煎西红柿汤的具体做法是:取自然熟透的小西红柿(50克左右)切碎,锅内放10克左右植物油,加热,放入适量葱花、食盐,待葱花飘出香味时将切碎的西红柿倒入锅中煎炒1-2分钟,再沏入适量水滚开出锅即可。
本发明各原料的作用:
肿节风,性味功效:味辛,性平。清热解毒,祛风除湿,活血止痛。临床应用:适用于多种肿瘤,如食管癌、胃癌、结肠癌、直肠癌、胰腺癌、肝癌、急性白血病等。
山豆根,为豆科植物广豆根的根。性寒味苦。功效为清火、解毒、消肿、止痛。主治:喉痛,喉风,喉痹,牙龈肿痛,喘满热咳,黄疸,下痢,热肿,疥癣,蛇虫犬咬伤。其对食管癌、鼻 咽癌、宫颈癌、膀胱癌、白血病细胞有抑制作用。成分药理:含总生物碱约0.93%,其中苦参碱(Matrine)0.52%,氧化苦参碱(Oxymatrine)0.35%,以及含槐树素(Sophoraponicin)、紫檀素(Pterorepine)、红车轴草根甙(TrifolirhiZin)、山槐素(Maackian)、广豆根素(Sophra)等。山豆根对肿瘤细胞的DNA和RNA合成有明显的抑制作用,从而阻断肿瘤细胞的增殖,能促进淋巴细胞转化,激发或增强淋巴细胞的细胞毒作用,提高T细胞比值,增强或调整巨噬细胞吞噬功能,还能调节内分泌,增强肾上腺皮质的功能,由此影响肿瘤的发生和发展。
山慈茹,性味甘、辛、凉,小毒。归肝、肾、肺、胃、大肠经。药效:败毒抗癌、消肿散结。临床应用:适用于多种肿瘤,主要用于乳腺癌,亦用于恶性淋巴瘤、甲状腺癌、皮肤癌、宫颈 癌、鼻咽癌、食管癌、白血病、胃癌等。此外,还适用于痈肿疔毒、淋巴结核、蛇咬伤及良性肿瘤,如甲状腺瘤、乳腺囊性增生、乳腺纤维瘤、血管瘤等。药用(1)败毒抗癌,用于癌瘤积毒。
庆巴消夏,为豆科植物榼藤的成熟种子。性味功效: 甘凉,清热解毒。临床应用:抗癌、杀虫、灭螺、催吐泻。
种子含甾醇、黄酮、酚性成分、氨基酸、有机酸。其三萜皂甙酸水解得甙元榼藤酸(entagenic acid)、阿拉伯糖和木糖;粗榼藤酸进行酸水解而得游离甲硫醇(CH(3)SH)和另一个三萜皂甙元刺囊酸(ehinocystic acid)。种子油所含各种脂肪酸的百分数为肉豆蔻酸0.3%、软脂酸9.1% 、硬脂酸4.4%、花生脂酸1.7%、山蕍酸1.6%、油酸35.8%、亚油酸46.7%、亚麻酸0.4%。
种子制成糊剂,局部应用治腺体炎性肿胀、腹痛,有退热作用,又作麻醉剂及催吐剂。种子水浸后烤炙则可除去麻醉性而供食用。茎皮可作收敛剂,用于外伤。木部用于皮肤病,茎的水浸液洗治疥癣。主治:心病,肾病,肝热病,中毒症之热证,自脉病。抗癌作用:种子核仁中含两种毒性皂甙,作用相似,毒性相等。板蓝根,板蓝根苦,寒。归心、胃经。功效 清热解毒,凉血,利咽。其化学成分为:菘蓝根含靛蓝、靛玉红、β-谷甾醇、棕榈酸、尿苷、次黄嘌呤、尿嘧啶、青黛酮和胡萝卜苷等。其药理作用是:本品对多种革兰氏阳性菌、革兰氏阴性菌及流感病毒、虫媒病毒、腮腺病毒均有抑制作用。可增强免疫功能;有明显的解热效果。本品所含靛玉红有显著的抗白血病作用;板蓝根多糖能降低实验动物血清胆固醇和甘油三酯的含量,并降低MDA含量,从而证明本品有抗氧化作用。
墓头回,(败酱科败酱属植物异叶败酱的全草及根茎。)性味功效: 味苦、微酸涩,性微寒。收敛,燥湿,止血。临床应用: 适用于多种肿瘤,如宫颈癌、卵巢肿瘤、绒毛膜上皮癌、肝癌、白血病等。
本发明的效果:
主治:白血病,特别是前期白血病,从根本上改善身体机能,控制肿瘤继续疯长并使其逐渐缩小最终消失,从而恢复身体健康。
兼治:胃癌、食管癌、咽喉癌、喷门癌、幽门癌、大肠癌等消化系统癌症。
本方的特点在于:
1、药味少,剂量小,花费低,不浪费。
2、所选的药味都是被现代医学药理实验证明是能够治癌特别是能够治疗白血病的。而已有的治癌验方、偏方中则总是有一些——甚至是超过半数以上的药物都是没有被现代医学药理实验证明是有治癌功能和作用的。
3、针对病灶,箭箭穿心,即所选药味都特别特别钟情于射中靶心,药到病除。而不是只要治癌,就一哄而上,结果是“龙”多反而不治水。
4、尽最大可能“中性化”,即所选药味总体上保持“中性”,不寒不燥,不热不凉。这样就能使患者在整个服药的周期内少吃苦头、少受煎熬。而真要是出现“上火”或者“下泄”的情况,则完全可以针对具体个体的具体情况,临时添加一点“止泄”、“降火”的药物具体解决。而不是一开始就想象着患者可能就会上吐或者下泻,而把一些不必要的药物添加进方子,使患者在很长很长的服药期间都一直服用,最终造成不良后果。
本发明的常规服用剂量、方法为:每日三次,每次1袋,空腹服用;服药期间勿食用比较辛辣比较甘甜等对胃肠道刺激性较大的食物。以煎西红柿汤做药引子服用,效果更佳。本药三个月为一疗程,一般服用二至三个疗程,最多服用四个疗程。
具体实施方式:将肿节风30g、山豆根30g、山慈菇5g、板蓝根15g 各放大10倍,清水清洗后,置于BT-2 不锈钢提取釜中,加7-9倍自来水后,加热至100℃恒温提取1小时左右,分离提取液,加压过滤,滤液备用。第二次提取:往提取釜内加入5-7倍量的自来水,加热至100℃恒温提取半小时左右,分离提取液,加压过滤,滤液备用。第三次提取:往提取釜内加入3-5倍量的自来水,加热至100℃恒温提取20分钟左右,分离提取液,加压过滤,滤液备用。浓缩:将三次的提取液合并,置于B-500 型三效真空高能蒸发浓缩器内,减压( 负200mmHg),加热至80℃,浓缩至相对密度1.10 ~ 1.20,备用。制粉:将庆巴消夏1g、墓回头10g各放大10倍,一同粉碎为末,过100目筛,备用。配料:在30万级洁净车间内,将上述药粉与前述浓缩物以及适量蜂蜜水一起置混合机中充分混合,搅拌均匀。烘干、粉碎:将混合均匀的药料置于烘箱中60-70℃烘烤4-5小时,然后粉碎,过100 目筛。造粒:将混合均匀的药料置入造粒机中造粒。整粒:将制好的颗粒进行整粒,过35目筛。干燥:将整好的颗粒置入热循环干燥箱内,80℃下通风干燥至水分< 8%。包装:先将制好的颗粒装入聚乙烯塑料小袋中,每袋7g,再将装好的小袋装盒、装箱、灭菌( 采用60Co 辐照,辐照剂量为8kGy)。入库:将辐照过的成品按先进先出的原则进行入库。
Claims (2)
1.回族中药六味血癌康颗粒及其制备方法,是由下列六味原料的重量配比制成的:
肿节风30g、 山豆根30g、山慈菇5g、庆巴消夏1g、
板蓝根15g、 墓回头10g
此方为一日一剂煎服的基本方,在实际应用时,还可根据患者的体质及病症情况,增加1-3味中医“天人合一、辩证论治”理论的“辨证配伍”药。
2.根据权利要求1 所述的回族中药六味血癌康颗粒的重量配比,其特征在于包括下述制备步骤:
A、 提取物的制备
(1)、提取
a、第一次提取:将上述中草药的重量除庆巴消夏、墓回头以外,全部放大10倍,清水清洗后,置于BT-2 不锈钢提取釜中,加7-9 倍自来水后,加热至100℃恒温提取1小时左右,分离提取液,加压过滤,滤液备用;
b、第二次提取:往提取釜内加入5-7倍量的自来水,加热至100℃恒温提取半小时左右,分离提取液,加压过滤,滤液备用;
c、第三次提取:往提取釜内加入3-5倍量的自来水,加热至100℃恒温提取20分钟左右,分离提取液,加压过滤,滤液备用;
(2)、浓缩
将三次的提取液合并,置于B-500 型三效真空高能蒸发浓缩器内,减压( 负200mmHg),加热至80℃,浓缩至相对密度1.10 ~ 1.20,备用;
(3)、制粉
将庆巴消夏1g、墓回头10g各放大10倍,一同粉碎为末,过100目筛,备用;
(4)、配料
在30 万级洁净车间内,将上述药粉与前述浓缩物以及适量蜂蜜水一起置混合机中充分混合,搅拌均匀;
(5)烘干、粉碎
将混合均匀的药料置于烘箱中60-70℃烘烤4-5小时,然后粉碎,过100 目筛;
(6)造粒
将混合均匀的药料置入造粒机中造粒;
(7)整粒
将制好的颗粒进行整粒,过35目筛;
(8)干燥
将整好的颗粒置入热循环干燥箱内,80℃下通风干燥至水分< 8%;
B、包装
先将制好的颗粒装入聚乙烯塑料小袋中,每袋7g,再将装好的小袋装盒、装箱、灭菌(采用60Co 辐照,辐照剂量为8kGy);
C、入库
将辐照过的成品按先进先出的原则进行入库。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510749261.8A CN106668518A (zh) | 2015-11-08 | 2015-11-08 | 回族中药六味血癌康颗粒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510749261.8A CN106668518A (zh) | 2015-11-08 | 2015-11-08 | 回族中药六味血癌康颗粒及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106668518A true CN106668518A (zh) | 2017-05-17 |
Family
ID=58857275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510749261.8A Withdrawn CN106668518A (zh) | 2015-11-08 | 2015-11-08 | 回族中药六味血癌康颗粒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106668518A (zh) |
-
2015
- 2015-11-08 CN CN201510749261.8A patent/CN106668518A/zh not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105853901A (zh) | 癌症病人放化疗期间服用的制剂及制法 | |
CN106668518A (zh) | 回族中药六味血癌康颗粒及其制备方法 | |
WO2020047963A1 (zh) | 一种益母草膏 | |
CN106668519A (zh) | 回族中药六味血癌康片及其制备方法 | |
CN106668531A (zh) | 回族中药六味血癌康丸及其制备方法 | |
CN106668704A (zh) | 回族中药参木胃癌散颗粒及其制备方法 | |
CN106668535A (zh) | 回族中药六味血癌康口服液及其制备方法 | |
CN105663551A (zh) | 胰腺癌患者术后服用的中药制剂及制法 | |
CN106668526A (zh) | 回族中药六味白血康丸及其制备方法 | |
CN106668735A (zh) | 回族中药食胃克癌颗粒及其制备方法 | |
CN105079310A (zh) | 一种用于止痛的中药组合物及其制备方法 | |
CN106668540A (zh) | 回族中药虫草血癌康片及其制备方法 | |
CN106668746A (zh) | 回族中药术风白血康颗粒及其制备方法 | |
CN106668525A (zh) | 回族中药虫草血癌康口服液及其制备方法 | |
CN106668734A (zh) | 回族中药术风白血康丸及其制备方法 | |
CN106668737A (zh) | 回族中药食胃克癌片及其制备方法 | |
CN106668719A (zh) | 回族中药食胃克癌丸及其制备方法 | |
CN106668699A (zh) | 回族中药术风白血康口服液及其制备方法 | |
CN106668536A (zh) | 回族中药虫草血癌康颗粒及其制备方法 | |
CN106668527A (zh) | 回族中药虫草血癌康丸及其制备方法 | |
CN106668521A (zh) | 回族中药六味白血康口服液及其制备方法 | |
CN106668541A (zh) | 回族中药六味白血康片及其制备方法 | |
CN106668726A (zh) | 回族中药术风白血康片及其制备方法 | |
CN106668534A (zh) | 回族中药六味白血康颗粒及其制备方法 | |
CN106668705A (zh) | 回族中药十味消癌颗粒及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170517 |